The FDA approved Ocugen’s expanded access program for the treatment of retinitis pigmentosa with OCU400, according to a press release.
“One major challenge with RP is that it can be caused by mutations in any of over 100 different genes, but most therapies focus on addressing just one gene,” Huma Qamar, MD, MPH, CMI, chief medical officer of Ocugen, told Healio. “OCU400 expresses a master regulator gene called NR2E3 that helps reestablish homeostasis within the retinal cell environment regardless of the underlying mutation, which will address an unmet need for over 98%